Wasdell Group granted HPRA licence at new EU headquarters24 Jan 2019
The new Irish facility will allow the company to continue to act as a gateway to Europe for its British and North American customers.
The Wasdell Group has been granted its Health Products Regulatory Authority (HPRA) licence for its new EU headquarters in Dundalk, Ireland.
Following a successful HPRA inspection in December 2018, the company - an outsourcing partner for companies in the pharmaceutical and clinical trials industries - is now certified to conduct Qualified Person (QP) batch certification and release of pharmaceutical products to Europe ahead of the facility commencing operations in Spring 2019.
Colin Newbould, Director of Regulatory Affairs and QP services at The Wasdell Group said: “Being accredited with this licence ahead of schedule is testament to our team.
“While this expansion will allow us to cater for increased customer demand, the Dundalk facility is also an integral part of our proactive contingency plan to protect our customers critical supply chains ahead of the UK’s exit from the European Union (EU).
“Receiving the HPRA licence is an important milestone, bringing us closer to finalising what has been a huge project for us. And, with the 29th March Brexit deadline just around the corner, it means our customers can be confident that we can manage any risk associated no matter the outcome.”
The €30-million investment into the Ireland facility was made in 2018 and forms part of the company’s ongoing plans to expand its offering outside of the UK.
The Dundalk facility will offer a full range of contract services including quality control (QC) import testing and batch release for pharmaceutical products, as well as a variety of current and novel packaging technologies. It will also house the company’s largest storage and distribution facilities to date.
Vincent Dunne, CEO of The Wasdell Group said: “With almost 75% of our turnover being a result of export business and a growing customer base in both the Irish and US markets, Dundalk was a logical choice for our EU headquarters.
“The new facility will allow us to continue to act as a gateway to Europe for our British and North American customers.”
The Irish facility comes as the latest phase in the company’s strategic plan to bolster capabilities and capacity, following the recent £500K investment into its new microbiological and analytical laboratory at its Newcastle, UK site.
Vetter's Skokie facility expansion nears completion
17 Apr 2019
Expansions will help meet an increase in customer projects; a second extension is in the final planning stage.Read more
Catalent to acquire gene therapy leader Paragon Bioservices
16 Apr 2019
Will provide new expertise and capabilities in one of the fastest-growing areas of healthcare.Read more
Colorcon expands functional film coatings through the CR Alliance with DuPont
15 Apr 2019
The Aquacoat product line provides modified release drug profiles with the added benefit of global regulatory acceptance.Read more
Hovione Technology acquires global rights to new pulmonary inhaler device
15 Apr 2019
The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.Read more
Exploristics surges ahead with £1m investment
15 Apr 2019
The loan will be used to develop KERUS Cloud - currently the only software that can simulate trials with multiple correlated outcomes - by integrating it into an intelligent software ecosystem.Read more
Catalent celebrates opening of second Shanghai facility
14 Apr 2019
Catalent’s two Shanghai locations will provide sponsors with an optimized supply solution for studies being undertaken in China, the Asia-Pacific region and globally.Read more
Global collaboration to innovate more natural and additive-free nutraceuticals
12 Apr 2019
Initiative will enable Sirio Pharma to keep abreast of regional trends, new ingredients, dosage forms and claims to provide customers unique product ideas for line extensions.Read more
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Sterling Pharma to acquire CiVentiChem in the US
9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.Read more
New China-based biotechs fueling growth in manufacturing across China
9 Apr 2019
New guidelines will see poorer quality manufacturers drop out of the market.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation